Study shows EnlighHTN RDS safe for Hypertension patients - St Jude Medical

St. Jude Medical has announced preliminary results from the EnligHTN III study, which found the EnligHTN renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled Hypertension six months post-procedure. Preliminary results confirmed safe, rapid and sustained reduction in blood pressure measurements for patients with drug-resistant hypertension, meaning their high blood pressure could not be controlled through medication.

Six-month EnligHTN III data showed an average systolic blood pressure reduction of 25 mmHg points, and that 81 percent of patients responded to the therapy, which is defined as a blood pressure reduction of at least 10 mmHg when measured during an office visit. Finally no serious device- or procedure-related adverse events were reported. The results were presented during EuroPCR 2014.